CH661870A5 - Composizione farmaceutica per la cura delle arteriopatie periferiche. - Google Patents
Composizione farmaceutica per la cura delle arteriopatie periferiche. Download PDFInfo
- Publication number
- CH661870A5 CH661870A5 CH4280/84A CH428084A CH661870A5 CH 661870 A5 CH661870 A5 CH 661870A5 CH 4280/84 A CH4280/84 A CH 4280/84A CH 428084 A CH428084 A CH 428084A CH 661870 A5 CH661870 A5 CH 661870A5
- Authority
- CH
- Switzerland
- Prior art keywords
- pharmaceutical composition
- defibrotide
- arteriopathies
- treatment
- peripheral
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 230000002093 peripheral effect Effects 0.000 title claims abstract description 8
- 229960004120 defibrotide Drugs 0.000 claims abstract description 16
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 200000000007 Arterial disease Diseases 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000013160 medical therapy Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000000019 pro-fibrinolytic effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000003558 thrombophilic effect Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22855/83A IT1170214B (it) | 1983-09-12 | 1983-09-12 | Composizione farmaceutica per la cura delle arteriopatie periferiche |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH661870A5 true CH661870A5 (it) | 1987-08-31 |
Family
ID=11201215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH4280/84A CH661870A5 (it) | 1983-09-12 | 1984-09-07 | Composizione farmaceutica per la cura delle arteriopatie periferiche. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5081109A (enExample) |
| EP (1) | EP0137543B1 (enExample) |
| JP (1) | JPH0647545B2 (enExample) |
| AT (1) | ATE55695T1 (enExample) |
| BE (1) | BE900564A (enExample) |
| CH (1) | CH661870A5 (enExample) |
| DE (1) | DE3433328A1 (enExample) |
| IT (1) | IT1170214B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1223322B (it) * | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
| IT1231509B (it) * | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
| US6699985B2 (en) | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| DE19610345C1 (de) | 1996-03-18 | 1997-11-20 | Krupp Vdm Gmbh | Katalysator zur Oxidation von Abwasserverunreinigungen mittels Persäuren und/oder Wasserstoffperoxid |
| CA2259041A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
| ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| EP1855697A2 (en) * | 2005-03-03 | 2007-11-21 | Gentium Spa | Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
| EP1891952B1 (en) * | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Pharmaceutical composition of olmesartan medoxomil |
| EP1872787A1 (en) * | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
| EP2103689A1 (en) | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| EP2637672B1 (en) | 2010-11-12 | 2018-08-22 | Gentium S.r.l. | Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd). |
| KR102038357B1 (ko) | 2012-06-22 | 2019-10-31 | 젠티엄 에스알엘 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| EP3661484A1 (en) | 2017-08-03 | 2020-06-10 | Jazz Pharmaceuticals Ireland Limited | Formulations comprising a nucleic acid in a high concentration |
| WO2019200251A1 (en) | 2018-04-12 | 2019-10-17 | Jazz Pharmaceuticals, Inc. | Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion |
| WO2020118165A1 (en) | 2018-12-07 | 2020-06-11 | Jazz Pharmaceuticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| US20230190783A1 (en) | 2020-02-28 | 2023-06-22 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| US20230086833A1 (en) | 2020-04-17 | 2023-03-23 | Jazz Pharmaceuticals Ireland Limited | Defibrotide treatment for the prevention of organ rejection and injury |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| US4485105A (en) * | 1978-10-12 | 1984-11-27 | American Cyanamid Company | Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides |
| GB2043072B (en) * | 1979-02-13 | 1983-11-23 | Symphar Sa | Diphosphonate compounds |
| US4416877A (en) * | 1979-02-13 | 1983-11-22 | Symphar S.A. | Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds |
| JPS5675474A (en) * | 1979-11-22 | 1981-06-22 | Chugai Pharmaceut Co Ltd | Nicotinamide derivative and medicine containing the same |
| US4351950A (en) * | 1980-01-02 | 1982-09-28 | Warner-Lambert Company | Anti-arteriosclerotic agents |
| US4450272A (en) * | 1982-05-06 | 1984-05-22 | American Cyanamid Company | Antiatherosclerotic 1-piperazine-thicarboxamides |
| IT1167197B (it) * | 1983-07-25 | 1987-05-13 | Bellon Roger Schoum Rbs Pharma | Impiego della fenpiramina quale farmaco antiaggregante piastrinico,vasodilatatore,antitrombotico e antianginoso |
| IT1170215B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
-
1983
- 1983-09-12 IT IT22855/83A patent/IT1170214B/it active
-
1984
- 1984-09-07 CH CH4280/84A patent/CH661870A5/it not_active IP Right Cessation
- 1984-09-07 AT AT84201287T patent/ATE55695T1/de active
- 1984-09-07 EP EP84201287A patent/EP0137543B1/en not_active Expired - Lifetime
- 1984-09-11 DE DE19843433328 patent/DE3433328A1/de active Granted
- 1984-09-12 BE BE0/213641A patent/BE900564A/fr not_active IP Right Cessation
- 1984-09-12 JP JP59191391A patent/JPH0647545B2/ja not_active Expired - Lifetime
-
1988
- 1988-07-05 US US07/218,514 patent/US5081109A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0647545B2 (ja) | 1994-06-22 |
| IT8322855A0 (it) | 1983-09-12 |
| EP0137543A2 (en) | 1985-04-17 |
| DE3433328A1 (de) | 1985-03-28 |
| DE3433328C2 (enExample) | 1993-08-05 |
| BE900564A (fr) | 1985-01-02 |
| JPS6169722A (ja) | 1986-04-10 |
| EP0137543B1 (en) | 1990-08-22 |
| US5081109A (en) | 1992-01-14 |
| EP0137543A3 (en) | 1987-09-02 |
| IT1170214B (it) | 1987-06-03 |
| ATE55695T1 (de) | 1990-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2320630T5 (es) | Método para la mejora de la señalización de los islotes en diabetes mellitus y para su prevención | |
| Mallory et al. | Selective intra-arterial vasopressin infusion for upper gastrointestinal tract hemorrhage: A controlled trial | |
| Panes et al. | Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices: results in 151 consecutive episodes | |
| Schafer | Effects of nonsteroidal anti-inflammatory therapy on platelets | |
| EP0137543B1 (en) | Use of defibrotide for the preparation of pharmaceutical compositions for the therapeutical treatment of peripheral arteriopathies | |
| ES2247716T3 (es) | Promotores de la neovascularizacion y potenciadores de la neovascularizacion. | |
| BR0008039A (pt) | Combinações de formoterol e um sal de tiotrópio | |
| ES2251095T3 (es) | Agentes terapeuticos para complicaciones diabeticas. | |
| ES2288878T3 (es) | Utilizacion de acido sulfodeshidroabietico para el tratamiento de enfermedades intestinales inflamatorias. | |
| ES2361915T3 (es) | Utilización de la betaína para el tratamiento de la claudicación intermitente. | |
| ES2289090T3 (es) | Medicamento para la administracion de amifostina y compuestos relacionados. | |
| CN117357525A (zh) | 一种trpml1高特异性小分子激动剂ml-sa5的应用 | |
| KR20240072071A (ko) | 줄기세포 스페로이드를 포함하는 조직 재생 촉진용 조성물 | |
| JP2004535396A (ja) | アミホスチン及び関連化合物を用いる化学防御 | |
| JP2000026300A (ja) | 血管内皮細胞保護医薬組成物 | |
| CN101198334A (zh) | 前列腺素化合物和质子泵抑制剂用于治疗肠胃病的联合应用 | |
| CA2079205C (en) | Use of hyaluronic acid and forms to prevent arterial restenosis | |
| Tilden et al. | Relapsing febrile nonsuppurative panniculitis: Report of two cases | |
| CN117752649A (zh) | 桑根酮c在制备抗血小板聚集、抗血栓形成药物中的应用 | |
| CN106822090B (zh) | 3,4,7-三羟基异黄酮或3-甲氧基大豆素在制备抑制血小板聚集和血栓药物中的应用 | |
| JP7609882B2 (ja) | イカリチンの医薬使用 | |
| Abate et al. | Monooctanoin use for gallstone dissolution | |
| ES2209922T3 (es) | Composiciones farmaceuticas que contienen una base 8-cloro-3(beta-dietilaminoetil)-4-metil-7-etoxicarbonil-metoxi cumarina y sus sales con actividad reductora de colesterol. | |
| Bergan | Ischemic necrosis of the tongue; a case report | |
| CN114075260B (zh) | 化合物p57或其类似物用于体温降低和神经保护的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |